Feb. 27 at 11:14 AM
$NEO 🚀 Why NeoGenomics (
$NEO) is Moving Today
1. The "Big Win": RaDaR ST Official Launch After years of legal handcuffs, NeoGenomics officially launched its RaDaR ST assay this week. This is their "Natera-killer"—a high-sensitivity test for cancer recurrence in a market worth over
$20 billion.
2. Legal "All-Clear" with Natera The lawsuit you saw regarding InVisionFirst-Lung was just settled. Combined with Natera dropping its major patent appeals in December, NeoGenomics now has zero major legal blockages for the first time in years. They are finally free to sell without fear of court injunctions.
3. Institutional "Relief Rally" The stock took a hit last week on 2026 guidance
$NTRA
1️⃣ RaDaR ST Launch: Officially live this week to challenge Natera's dominance in the
$20B cancer-tracking market.
2️⃣ Legal Peace: Settled the InVisionFirst suit with
$NTRA; patent "war" is essentially over.
3️⃣ Commercial Era: No more courtroom drama—just pure growth and market share capture.
